A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder
← catalyst calendarNCT07071532 · readout ≤ 192 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Basic science
Enrollment
20estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-21 | estimated | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Bipolar Disorder
Interventions
- Drug: ABBV-932
- Drug: Itraconazole — also filed as ITZ
Primary outcomes
what the primary-completion date above is the date OFMaximum Plasma Concentration (Cmax) of ABBV-932 and active metabolites DCAR and DDCAR
measured Up to approximately 29 days
Time to Cmax (Tmax) of ABBV-932 and active metabolites DCAR and DDCAR
measured Up to approximately 29 days
Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-932 and active metabolites DCAR and DDCAR
measured Up to approximately 29 days
Apparent terminal phase elimination rate constant (β) of ABBV-932 and active metabolites DCAR and DDCAR
measured Up to approximately 29 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-932 and active metabolites DCAR and DDCAR
measured Up to approximately 29 days
Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932 and active metabolites DCAR and DDCAR
measured Up to approximately 29 days
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932 and active metabolites DCAR and DDCAR
measured Up to approximately 29 days
Number of Participants Experiencing Adverse Events
measured Up to approximately 61 days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed